Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
Press releases published on July 31, 2025
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025
GlobeNewswire
·
July 31, 2025
Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19% Operating cash flow of $539 million Quarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. …
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
GlobeNewswire
·
July 31, 2025
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: …
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
GlobeNewswire
·
July 31, 2025
Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical …
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
GlobeNewswire
·
July 31, 2025
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven …
Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call
GlobeNewswire
·
July 31, 2025
RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on …
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025
GlobeNewswire
·
July 31, 2025
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial …
Orchestra BioMed Announces Proposed Public Offering
GlobeNewswire
·
July 31, 2025
NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced …
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
GlobeNewswire
·
July 31, 2025
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an …
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
GlobeNewswire
·
July 31, 2025
COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial …
scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025
GlobeNewswire
·
July 31, 2025
BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire
·
July 31, 2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 7, 2025 at 4:30 pm ET …
Solésence Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
July 31, 2025
ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, …
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
GlobeNewswire
·
July 31, 2025
Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le …
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
GlobeNewswire
·
July 31, 2025
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the …
Nephros Schedules Second Quarter 2025 Financial Results Conference Call
GlobeNewswire
·
July 31, 2025
SOUTH ORANGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its second-quarter financial …
J-Star Holding Announces Closing of $5.0 Million Initial Public Offering
GlobeNewswire
·
July 31, 2025
TAICHUNG CITY, Taiwan, July 31, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, …
PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial
GlobeNewswire
·
July 31, 2025
PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial FDA agreed that PolTREG’s clinical data in Stage 3 Type 1 Diabetes (T1D) appears sufficient to support the Prospect …
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
·
July 31, 2025
Access the “What This Means” segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the …
BCC Research Publishes 2024 Plastics Market Review Highlighting Bioplastics, Recycling, and Industry Transformation
GlobeNewswire
·
July 31, 2025
Boston, July 31, 2025 (GLOBE NEWSWIRE) -- BCC Research announces the release of its "2024 Plastics Research Review,” which explores the evolving landscape of the global plastics industry. With increasing emphasis on sustainability, regulatory change, and …
Chronic Pain Associated with Painful Diabetic Neuropathy Market Sees is Predicted to Surge During the Forecast Period (2025–2034) with New Treatment Innovations and Expanding Research Spending | DelveInsight
GlobeNewswire
·
July 31, 2025
New York, USA, July 31, 2025 (GLOBE NEWSWIRE) -- Chronic Pain Associated with Painful Diabetic Neuropathy Market Sees is Predicted to Surge During the Forecast Period (2025–2034) with New Treatment Innovations and Expanding Research Spending | DelveInsight …